Date | Price Target | Rating | Analyst |
---|---|---|---|
9/16/2024 | $16.00 | Neutral → Buy | Ladenburg Thalmann |
4/29/2024 | Buy → Neutral | Ladenburg Thalmann | |
3/1/2024 | $14.00 | Mkt Outperform | JMP Securities |
12/15/2023 | $17.00 → $12.00 | Buy | Jefferies |
10/5/2023 | Buy | Maxim Group | |
6/2/2023 | $25.00 | Outperform | Oppenheimer |
5/8/2023 | $25.00 | Outperform | BMO Capital Markets |
4/27/2023 | $22.00 | Buy | Ladenburg Thalmann |
Ladenburg Thalmann upgraded Acrivon Therapeutics from Neutral to Buy and set a new price target of $16.00
Ladenburg Thalmann downgraded Acrivon Therapeutics from Buy to Neutral
JMP Securities initiated coverage of Acrivon Therapeutics with a rating of Mkt Outperform and set a new price target of $14.00
Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically significant segregation of responders in BM+ vs BM- subgroups based on OncoSignature patient selection (p-value = 0.009) ACR-368 endometrial cohort data maturing with all responders still on therapy; mDoR not yet reached (~6 months at time of data-cut) Endometrial cancer now anticipated to be the first tumor type with potential for ACR-368 accelerated regulatory approval IND clearance and initial sites activated ahead of timelines for ACR-2316 with first-in-human dosing anticipated in Q4 2024 AP3
WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, September 17, 2024 at 8:35 a.m. ET at the Cantor Global Healthcare Conference in New York. To access the live webcast, visit the Events
-Webcast investor event on September 14, 2024 at 9:00 a.m. ET -ESMO poster presentation to provide updated ACR-368 clinical data in endometrial cancer -Webcast to provide updates on its lead assets ACR-368, ACR-2316, and its AP3 platform WATERTOWN, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today announced that the company will host a
8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
10-Q - Acrivon Therapeutics, Inc. (0001781174) (Filer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
BMO Capital analyst Etzer Darout reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and maintains $25 price target.
HC Wainwright & Co. analyst Emily Bodnar maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and raises the price target from $20 to $22.
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.84) by 13.1 percent. This is a 25.86 percent decrease over losses of $(0.58) per share from the same period last year.
WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided business highlights. "On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year
WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors. "Santhosh previously served as an advisor to Acrivon and has a deep understanding and appreciation of the breadth and novelty of our next generation precisi
WATERTOWN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D., to its board of directors. "We are excited to welcome Ivana to our board of directors," said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and fou